BMS' second small-cell trial flop endangers Opdivo lung cancer approval: analyst

cafead

Administrator
Staff member
  • cafead   Nov 28, 2018 at 12:02: AM
via Bristol-Myers Squibb’s Opdivo has failed another small-cell lung cancer trial—and now, its Yervoy combination approval in the disease could be in jeopardy.

article source